Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.51 |
| ▸ | NEU1 | Q99519 | 10/20 | 0.33 |
| ▸ | NEU2 | Q9Y3R4 | 6/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Krn5500 SCHEMBL31060330 | 0.86 | PAX8 (0.42) | PAX8 | |
| Krn5500 SCHEMBL17314988 | 0.86 | PAX8 (0.42) | PAX8 | |
| Krn5500 SCHEMBL2357505 | 0.86 | PAX8 (0.42) | PAX8 | |
| Krn5500 SCHEMBL29395534 | 0.86 | PAX8 (0.42) | PAX8 | |
| SCHEMBL17091588 | 0.86 | PAX8 (0.42) | PAX8 | |
| SCHEMBL11647749 | 0.84 | PAX8 (0.65) | PAX8XDH | |
| SCHEMBL11649574 | 0.84 | PAX8 (0.65) | PAX8XDH | |
| SCHEMBL11651183 | 0.84 | PAX8 (0.65) | PAX8XDH | |
| SCHEMBL11651719 | 0.84 | PAX8 (0.65) | PAX8XDH | |
| SCHEMBL29351487 | 0.80 | PAX8 (0.80) | PAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632825-B2 | Methods of decreasing or preventing pain using spicamycin derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-12-15 | — | — | US | disclosed |
| US-20080207557-A1 | Methods of Decreasing or Preventing Pain Using Spicamycin Derivatives | MIDATECH PHARMA PLC (GB) | 2008-08-28 | — | — | US | disclosed |
| US-7375094-B2 | Methods for decreasing or preventing pain using spicamycin derivatives | THE GENERAL HOSPITAL CORPORATION (US) | 2008-05-20 | — | — | US | disclosed |
| US-20070161597-A1 | Methods for Decreasing or Preventing Pain Using Spicamycin Derivatives | MIDATECH PHARMA PLC (GB) | 2007-07-12 | — | — | US | disclosed |
| US-7196071-B2 | Methods of decreasing or preventing pain using spicamycin derivatives | THE GENERAL HOSPITAL CORPORATION (US) | 2007-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161597-A1 | Methods for Decreasing or Preventing Pain Using Spicamycin Derivatives | NPSR1, SPAST, NISCH | PAX8 1715/4885NEU1 423/4885NEU2 247/4885 |
| US-20080207557-A1 | Methods of Decreasing or Preventing Pain Using Spicamycin Derivatives | NPSR1, SPAST, OPRL1 | PAX8 1745/4885NEU1 394/4885NEU2 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.